Jubbonti ® (denosumab-bbdz) and Wyost ® (denosumab-bbdz), interchangeable biosimilars to Prolia ® (denosumab) and Xgeva ® (denosumab), respectively, are now available from Sandoz. The ...

Health care data breaches that compromised protected health information more than doubled from 2010 to 2024 in the US, data suggest.

The study will assess the number and severity of dose-limiting toxicities and adverse events. A new study will evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells ...

Engaging in leisure-time MVPA linked to improved survival for various cancer types including bladder, breast, colon. (HealthDay News) — Engaging in leisure-time moderate- to vigorous-intensity ...

Patients with prostate cancer may have a lower risk of recurrence if they take multivitamin supplements after diagnosis, new data suggest.

Adding zilebesiran to a thiazide diuretic or calcium channel blocker may lead to further blood pressure reduction in patients with uncontrolled hypertension. Zilebesiran added to hypertension ...

One-year incidence of psychosocial therapy initiation was 12.6 percent, while incidence of medication initiation was 2.8 percent ...

Phase 3 trial results suggest that adjuvant treatment with mitomycin and bacillus Calmette-Guérin (BCG) is as safe and effective as BCG alone for patients with high-risk non-muscle invasive bladder ...

A prospective study of sex hormone use in patients seeking transgender treatments suggests how these hormones may influence kidney health.

Only incidence and prevalence rates attributable to keratinocyte cancer, DALYs attributable to BCC would increase by 2050 ...

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes.